united therapeutics glp-1 receptor agonist Biased agonism and polymorphic variation at the receptor: Implications for the development of personalised GLP-1 Receptor Agonists: The New
Description
Back Diem, P, Ducluzeau, PH, Scheen, A (Jan-March 2022) 'The discovery of insulin', Diabetes, Epidemiology and Management , 5, 100049
That is a 20% dose reduction
Learn more about the key factors that healthcare professionals consider, including BMI, weight loss attempts, health issues, psychological well-being, commitment to lifestyle changes, and more
The short half-life of native GLP- 1-based therapy in the circulation (approximately two minutes after intravenous administration and one to five hours after subcutaneous administration) posed a problem during its early development [9]
2016;310:E74453
Molecular and cellular responses of islets during perturbations of glucose homeostasis determined by in situ hybridization histochemistry
